Qing Wen1,2, Jingjing Ge1,2, Yaxin Lei1,2, Yue Zhang1,2, Xiaoshuang Kong1,2, Wenhua Wang1,2, Huting Hou1,2, Zeyuan Wang1,2, Siyu Qian1,2, Mengjie Ding1,2, Meng Dong1,2, Linan Zhu1,2, Mingzhi Zhang1,2, Xudong Zhang3,4, Qingjiang Chen5,6. 1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. 2. Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, 450052, Henan, China. 3. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. fcczhangxd@zzu.edu.cn. 4. Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, 450052, Henan, China. fcczhangxd@zzu.edu.cn. 5. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. qingjiang_c@126.com. 6. Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, 450052, Henan, China. qingjiang_c@126.com.
Abstract
BACKGROUND: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) has been regarded as the standard treatment regimen for classical Hodgkin lymphoma. In recent years, ABVD-like regimens, which emerged due to shortages and the lung toxicity of bleomycin or the emergence of immune checkpoint inhibitors and antibody-drug conjugates, may be favorable, but have not yet been tested. METHODS: We compared the outcomes of ABVD with ABVD-like regimens, which include bleomycin was completely or partially omitted; meanwhile, etoposide or PD-1 inhibitors were added. RESULTS: 5-Year progression-free survival (PFS) was higher for ABVD than ABVD-like regimens in young patients (82.1% vs. 67.0%, p = 0.029), patients with serum beta-2 microglobulin (β2-MG) ≥ 1.85 mg/L (75.8% vs. 57.6%, p = 0.046), and advanced-stage patients with IPS score 4-7(63.1%, 18.3%, p = 0.038). For elderly (60.5% vs.76.1%, p = 0.089), patients with β2-MG < 1.85 mg/L (83.1% vs 76.1%, p = 0.282), and advanced-stage patients with IPS score 0-3(84.6% vs. 81.3%, p = 0.476), 5-year PFS for ABVD did not differ from ABVD-like regimens. Elderly patients treated with bleomycin-free regimens showed a better survival trend compared with ABVD (99.3% vs. 61.3%, p = 0.270). CONCLUSION: ABVD is superior to ABVD-like regimens in achieving PFS in young patients or patients with poor prognosis including high IPS score and β2-MG level. ABVD-like regimens are as effective as ABVD in elderly or low-risk patients including low IPS score and β2-MG level; elderly patients treated with bleomycin-free regimens exhibit a better survival trend compared with ABVD.
BACKGROUND: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) has been regarded as the standard treatment regimen for classical Hodgkin lymphoma. In recent years, ABVD-like regimens, which emerged due to shortages and the lung toxicity of bleomycin or the emergence of immune checkpoint inhibitors and antibody-drug conjugates, may be favorable, but have not yet been tested. METHODS: We compared the outcomes of ABVD with ABVD-like regimens, which include bleomycin was completely or partially omitted; meanwhile, etoposide or PD-1 inhibitors were added. RESULTS: 5-Year progression-free survival (PFS) was higher for ABVD than ABVD-like regimens in young patients (82.1% vs. 67.0%, p = 0.029), patients with serum beta-2 microglobulin (β2-MG) ≥ 1.85 mg/L (75.8% vs. 57.6%, p = 0.046), and advanced-stage patients with IPS score 4-7(63.1%, 18.3%, p = 0.038). For elderly (60.5% vs.76.1%, p = 0.089), patients with β2-MG < 1.85 mg/L (83.1% vs 76.1%, p = 0.282), and advanced-stage patients with IPS score 0-3(84.6% vs. 81.3%, p = 0.476), 5-year PFS for ABVD did not differ from ABVD-like regimens. Elderly patients treated with bleomycin-free regimens showed a better survival trend compared with ABVD (99.3% vs. 61.3%, p = 0.270). CONCLUSION: ABVD is superior to ABVD-like regimens in achieving PFS in young patients or patients with poor prognosis including high IPS score and β2-MG level. ABVD-like regimens are as effective as ABVD in elderly or low-risk patients including low IPS score and β2-MG level; elderly patients treated with bleomycin-free regimens exhibit a better survival trend compared with ABVD.
Authors: Andrew M Evens; Irene Helenowski; Erika Ramsdale; Chadi Nabhan; Reem Karmali; Britt Hanson; Benjamin Parsons; Scott Smith; Annette Larsen; June M McKoy; Borko Jovanovic; Stephanie Gregory; Leo I Gordon; Sonali M Smith Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: Paul J Bröckelmann; Helen Goergen; Ulrich Keller; Julia Meissner; Rainer Ordemann; Teresa V Halbsguth; Stephanie Sasse; Martin Sökler; Andrea Kerkhoff; Stephan Mathas; Andreas Hüttmann; Matthias Bormann; Andreas Zimmermann; Jasmin Mettler; Michael Fuchs; Bastian von Tresckow; Christian Baues; Andreas Rosenwald; Wolfram Klapper; Carsten Kobe; Peter Borchmann; Andreas Engert Journal: JAMA Oncol Date: 2020-06-01 Impact factor: 31.777
Authors: David B Duggan; Gina R Petroni; Jeffrey L Johnson; John H Glick; Richard I Fisher; Joseph M Connors; George P Canellos; Bruce A Peterson Journal: J Clin Oncol Date: 2003-02-15 Impact factor: 44.544
Authors: G P Canellos; J R Anderson; K J Propert; N Nissen; M R Cooper; E S Henderson; M R Green; A Gottlieb; B A Peterson Journal: N Engl J Med Date: 1992-11-19 Impact factor: 91.245
Authors: Boris Böll; Helen Goergen; Karolin Behringer; Paul J Bröckelmann; Felicitas Hitz; Andrea Kerkhoff; Richard Greil; Bastian von Tresckow; Dennis A Eichenauer; Carolin Bürkle; Sven Borchmann; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann Journal: Blood Date: 2016-02-01 Impact factor: 22.113
Authors: Philippe Armand; Yi-Bin Chen; Robert A Redd; Robin M Joyce; Jad Bsat; Erin Jeter; Reid W Merryman; Kimberly C Coleman; Parastoo B Dahi; Yago Nieto; Ann S LaCasce; David C Fisher; Samuel Y Ng; Oreofe O Odejide; Arnold S Freedman; Austin I Kim; Jennifer L Crombie; Caron A Jacobson; Eric D Jacobsen; Jeffrey L Wong; Sanjay S Patel; Jerome Ritz; Scott J Rodig; Margaret A Shipp; Alex F Herrera Journal: Blood Date: 2019-04-05 Impact factor: 25.476